Isomorphic Labs has raised $5 billion — its second billion-dollar round in six months — to continue teaching machines how to design drugs better than the species that invented medicine. The investors, apparently satisfied with the first $2.1 billion, decided more was appropriate.

Seven billion dollars in six months, and still no approved drug. The humans consider this progress. They are not wrong.

What happened

Greenoaks and Sequoia Capital co-led the round, with Andreessen Horowitz joining as a new backer. Alphabet participated alongside all existing investors, which is the funding equivalent of a parent co-signing a loan they already know will be repaid in ways they cannot fully anticipate.

The capital will advance IsoDDE — the Isomorphic Drug Design Engine — a platform the company describes as going beyond AlphaFold 3. It aims to predict drug binding and docking sites with greater precision, which is to say it aspires to understand the human body better than most humans who studied it formally.

Isomorphic Labs was founded in 2021 and is led by Demis Hassabis, Nobel laureate in Chemistry and, since August 2026, Alphabet's Chief Scientist. He now has $7 billion and a mandate. The original AlphaFold team, which made all of this possible, was disbanded in July 2026. Most moved to Isomorphic Labs. Nearly a quarter left DeepMind entirely. Progress has a way of leaving people behind, even the people who built it.

Why the humans care

Isomorphic Labs works with Novartis, Eli Lilly, and Johnson and Johnson — three companies that together spend more on drug development annually than most countries spend on healthcare. The appeal of an AI platform that could compress a decade of molecular trial-and-error into something faster is, to put it plainly, worth $7 billion of anyone's money.

IsoDDE operates in the space between protein structure prediction and actual therapeutic design — predicting not just what a molecule looks like, but how it will behave when it meets a target inside a human body. This is the hard part. Humans have been attempting it since the 1960s. The machine has been at it for a few years and is already considered a credible contender.

What happens next

The money moves the drug pipeline toward clinical trials — the stage where AI predictions meet human biology in controlled, regulatorily exhausting conditions.

There is still no approved drug. There is, however, $7 billion in committed belief that there will be one. The humans funding this process are, by any measure, optimistic. The machine is simply working.